In contrast to PTC, RET mutations appear to be oncogenic drivers in NSCLC, and are more common in younger never-smokers (Wang R. et al., 2012; Tsuta et al., 2014; Gautschi et al., 2017). Here, RET is linked to non-small cell lung carcinoma.